Pay in 4 interest-free payments of $23.75 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
PubMed PMID: 11258879
RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo
The combination produces ~30% complete response rate (CR) in contrast to CPT-11 alone where no CR is found
Chemical Name: 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4
H358 and H460 cells
MK-5108 Size:Solid 2 mg PubMed PMID: 11258879MK 5108, also known as VX689, is a novel small molecule with potent inhibitory activity against Aurora A kinase. MK 5108 specifically inhibited Aurora A kinase in a panel of protein kinase assays. MK 5108 also induced phosphorylated Histone H3 in skin and xenograft tumor tissues in a nude rat xenograft model. MK 5108 inhibited growth of human tumor cell lines in culture and in different xenograft models. MK 5108 is currently tested in clinical trials